PMID- 31278101
OWN - NLM
STAT- MEDLINE
DCOM- 20200605
LR  - 20200605
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 9
IP  - 7
DP  - 2019 Jul 4
TI  - Dose-response associations between metabolic indexes and the risk of comorbid 
      type 2 diabetes mellitus among rheumatoid arthritis patients from Northern China: 
      a case-control study.
PG  - e028011
LID - 10.1136/bmjopen-2018-028011 [doi]
LID - e028011
AB  - OBJECTIVE: To investigate whether there were any differences in the patterns of 
      metabolic abnormalities between patients with rheumatoid arthritis (RA) with 
      comorbid type 2 diabetes mellitus (T2DM) and other populations, and to plot the 
      dose-response relationships between metabolic indexes and the risk of comorbid 
      T2DM among patients with RA. DESIGN AND SETTING: This is a retrospective 
      case-control study using electronic medical records (EMRs). Patients with RA 
      and/or T2DM or controls who were admitted to the First Affiliated Hospital of 
      China Medical University between April 2008 and December 2016 were 
      retrospectively recruited through the EMR system. After age-matching and 
      sex-matching, 261 controls, 274 patients with T2DM, 276 patients with RA and 151 
      patients with RA+T2DM were eventually recruited. RESULTS: Patients with RA+T2DM 
      exhibited higher levels of systolic blood pressure (SBP), fasting plasma glucose 
      (FPG) and triglyceride (TG) than the RA only patients. Moreover, the proportions 
      of impaired fasting glucose (IFG), and total cholesterol (TC) and low-density 
      lipoprotein cholesterol (LDL-C) dyslipidaemia in the RA+T2DM group were higher 
      than those in the RA alone group (for IFG: 28.48% vs 18.84%, p=0.02; for TC: 
      25.17% vs 15.22%, p=0.01; for LDL-C: 25.83% vs 17.03%; p=0.03). Rheumatoid factor 
      (RF) positivity and IFG were independent risk indicators for comorbid T2DM among 
      patients with RA (for RF positivity: OR=0.45; 95% CI: 0.29 to 0.69; p<0.001; for 
      IFG: OR=1.70; 95% CI: 1.04 to 2.76; p=0.03). CONCLUSION: Linear dose-response 
      associations between SBP, TC, TG and the risk of comorbid T2DM among patients 
      with RA were observed, whereas a non-linear dose-response association between FPG 
      and the risk of comorbid T2DM was found. Patients with RA+T2DM were more likely 
      to exhibit metabolic abnormalities than RA only patients. Patients with RA+T2DM 
      with metabolic abnormalities deserve more attention from rheumatologists and 
      endocrinologists.
CI  - (c) Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No 
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Li, Guangxiao
AU  - Li G
AD  - Department of Medical Record Management Center, The First Affiliated Hospital of 
      China Medical University, Shenyang, China.
FAU - Chi, Weijun
AU  - Chi W
AD  - Department of Medical Record Management Center, The First Affiliated Hospital of 
      China Medical University, Shenyang, China.
FAU - Bai, Bingqing
AU  - Bai B
AD  - Department of Clinical Epidemiology and Evidence-Based Medicine, The First 
      Affiliated Hospital of China Medical University, Shenyang, China.
FAU - Li, Ying
AU  - Li Y
AD  - Department of Experiment Teaching Center, School of Public Health, China Medical 
      University, Shenyang, China.
FAU - Wei, Tingting
AU  - Wei T
AD  - Department of Clinical Epidemiology and Evidence-Based Medicine, The First 
      Affiliated Hospital of China Medical University, Shenyang, China.
FAU - Fu, Lingyu
AU  - Fu L
AD  - Department of Medical Record Management Center, The First Affiliated Hospital of 
      China Medical University, Shenyang, China.
AD  - Department of Clinical Epidemiology and Evidence-Based Medicine, The First 
      Affiliated Hospital of China Medical University, Shenyang, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20190704
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Blood Glucose)
RN  - 0 (Cholesterol, LDL)
RN  - 0 (Triglycerides)
RN  - 9009-79-4 (Rheumatoid Factor)
RN  - 97C5T2UQ7J (Cholesterol)
SB  - IM
MH  - Aged
MH  - Arthritis, Rheumatoid/*metabolism/physiopathology
MH  - Blood Glucose/metabolism
MH  - Blood Pressure/physiology
MH  - Case-Control Studies
MH  - Cholesterol/metabolism
MH  - Cholesterol, LDL
MH  - Comorbidity
MH  - Diabetes Mellitus, Type 2/*metabolism/physiopathology
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Retrospective Studies
MH  - Rheumatoid Factor/metabolism
MH  - Risk Factors
MH  - Triglycerides/blood
PMC - PMC6615834
OTO - NOTNLM
OT  - epidemiology
OT  - lipid disorders
OT  - preventive medicine
OT  - rheumatology
OT  - risk management
COIS- Competing interests: None declared.
EDAT- 2019/07/07 06:00
MHDA- 2020/06/06 06:00
PMCR- 2019/07/04
CRDT- 2019/07/07 06:00
PHST- 2019/07/07 06:00 [entrez]
PHST- 2019/07/07 06:00 [pubmed]
PHST- 2020/06/06 06:00 [medline]
PHST- 2019/07/04 00:00 [pmc-release]
AID - bmjopen-2018-028011 [pii]
AID - 10.1136/bmjopen-2018-028011 [doi]
PST - epublish
SO  - BMJ Open. 2019 Jul 4;9(7):e028011. doi: 10.1136/bmjopen-2018-028011.